Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
Aging (Albany NY) ; 12(15): 15784-15796, 2020 08 15.
Article in English | MEDLINE | ID: covidwho-721666

ABSTRACT

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), an epidemic disease characterized by rapid infection and a high death toll. The clinical diagnosis of patients with COVID-19 has risen sharply, especially in Western countries. Globally, an effective treatment for COVID-19 is still limited. Vitamin A (VA) exhibits pharmacological activity in the management of pneumonia. Thus, we reason that VA may potentially serve as an anti-SARS-CoV-2 regimen. In this study, bioinformatics analysis and computation assays using a network pharmacology method were conducted to explore and uncover the therapeutic targets and mechanisms of VA for treating COVID-19. We identified candidate targets, pharmacological functions, and therapeutic pathways of VA against SARS-CoV-2. Bioinformatics findings indicate that the mechanisms of action of VA against SARS-CoV-2 include enrichment of immunoreaction, inhibition of inflammatory reaction, and biological processes related to reactive oxygen species. Furthermore, seven core targets of VA against COVID-19, including MAPK1, IL10, EGFR, ICAM1, MAPK14, CAT, and PRKCB were identified. With this bioinformatics-based report, we reveal, for the first time, the anti-SARS-CoV-2 functions and mechanisms of VA and suggest that VA may act as a potent treatment option for COVID-19, a deadly global epidemic.


Subject(s)
Betacoronavirus , Coronavirus Infections , Immunity/drug effects , Inflammation , Pandemics , Pneumonia, Viral , Vitamin A , Betacoronavirus/drug effects , Betacoronavirus/genetics , Betacoronavirus/physiology , Biological Availability , COVID-19 , Computational Biology/methods , Coronavirus Infections/drug therapy , Coronavirus Infections/epidemiology , Coronavirus Infections/immunology , Gene Ontology , Humans , Inflammation/drug therapy , Inflammation/etiology , Inflammation/immunology , Pneumonia, Viral/drug therapy , Pneumonia, Viral/epidemiology , Pneumonia, Viral/immunology , SARS-CoV-2 , Signal Transduction/drug effects , Vitamin A/pharmacokinetics , Vitamin A/therapeutic use , Vitamins/pharmacokinetics , Vitamins/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL